Virax Biolabs Group Limited
VRAXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeVirax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and. Valued at $2.1M, VRAX is a micro-cap name in its sector. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease.
Market Cap
$2.1M
Beta
1.35
P/E (TTM)
—
P/E (Fwd)
-0.44
EPS (TTM)
$-12.64
EPS (Fwd)
$-6.00
ROE
-78.6%
ROA
-54.2%
Cash
$6.5M
Total Debt
$414,387
Free CF
-$3.5M
52W Change
-81.9%
Annual Financials
Cash vs Debt
Where VRAX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, VRAX finished 39.95% below its 150-day moving average ($4.23) and 54.96% below its 200-day moving average ($5.64). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VRAX overbought or oversold?
At the September 3, 2026 close, VRAX's RSI(14) was 43.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Virax Biolabs Group Limited holds $6.5M in cash against $414K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$3.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -78.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $9K (2023) to $12K (2026), reflecting a 45% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Virax Biolabs Group Limited's trajectory.